Cargando…

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells

BACKGROUND: Patients affected by aggressive B-cell malignancies who are resistant to primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited therapeutic options. Promising therapeutic success has been achieved with the infusion of CD19 chimeric antigen receptor-T cells, bu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietà, Anna Dalla, Cappuzzello, Elisa, Palmerini, Pierangela, Ventura, Annavera, Visentin, Andrea, Astori, Giuseppe, Chieregato, Katia, Mozzo, Valentina, Perbellini, Omar, Tisi, Maria Chiara, Trentin, Livio, Visco, Carlo, Ruggeri, Marco, Sommaggio, Roberta, Rosato, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287629/ https://www.ncbi.nlm.nih.gov/pubmed/34272306 http://dx.doi.org/10.1136/jitc-2021-002475

Ejemplares similares

Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
por: Sommaggio, Roberta, et al.
Publicado: (2020)

How can Cytokine-induced killer cells overcome CAR-T cell limits
por: Cappuzzello, Elisa, et al.
Publicado: (2023)

Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies
por: Cappuzzello, Elisa, et al.
Publicado: (2016)

High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting enzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources
por: Amati, Eliana, et al.
Publicado: (2018)

A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells
por: Chieregato, Katia, et al.
Publicado: (2021)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma
por: Sun, Haibo, et al.
Publicado: (2021)

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition
por: Crist, McKenzie, et al.
Publicado: (2022)

Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use
por: Amati, Eliana, et al.
Publicado: (2017)

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma
por: Chu, Yaya, et al.
Publicado: (2020)

Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice
por: Zobel, Michael John, et al.
Publicado: (2020)

Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1
por: Tosi, Anna, et al.
Publicado: (2017)

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017)

Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19
por: Osman, Mohammed, et al.
Publicado: (2020)

Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity
por: Kedia-Mehta, Nidhi, et al.
Publicado: (2021)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
por: Perry, Lauren M, et al.
Publicado: (2023)

Off-the-shelf CAR–engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia
por: Mansour, Anthony G., et al.
Publicado: (2023)

Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
por: Pollack, Karlyn E, et al.
Publicado: (2020)

A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
por: Griguolo, Gaia, et al.
Publicado: (2022)

Bringing natural killer cells to the clinic
por: Chiossone, Laura, et al.
Publicado: (2022)

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

The production method affects the efficacy of platelet derivatives to expand mesenchymal stromal cells in vitro
por: Bernardi, Martina, et al.
Publicado: (2017)

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
por: Cortellini, Alessio, et al.
Publicado: (2021)

An (89)Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor
por: Mason, Christian A., et al.
Publicado: (2020)

IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
por: Vitanza, Nicholas, et al.
Publicado: (2020)

IMMU-10. INTERIM ANALYSIS OF THE HIT-HGG REZ IMMUNVAC STUDY - DENDRITIC CELL VACCINATION WITH PARTIAL TREG DEPLETION IN CHILDREN, ADOLESCENTS, AND ADULTS WITH RELAPSED HIGH-GRADE GLIOMAS
por: Eyrich, Matthias, et al.
Publicado: (2020)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

IMMU-05. B7-H3-SPECIFIC CAR T CELLS HAVE POTENT ANTI-TUMOR ACTIVITY IN THE GL261 IMMUNE-COMPETENT MURINE BRAIN TUMOR MODEL
por: Haydar, Dalia, et al.
Publicado: (2020)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

IMMU-21. INVESTIGATION OF WHITE BLOOD CELL CHARACTERISTICS IN CSF SAMPLES AT PEDIATRIC BRAIN TUMOR DIAGNOSIS
por: Greer, Hunter, et al.
Publicado: (2020)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r833ts84af91e4r9tllk5qje95